Xarelto Lawsuit Loans

Have a Xarelto Settlement? Need Cash?

TriMark Legal Funding can put some cash in your hands before your Xarelto case has settled.

Xarelto Lawsuit Loans

TriMark Legal Funding has been helping plaintiffs who need financial assistance through affordable non-recourse pre settlement funding for 17 years now.  We offer Xarelto lawsuit loans to victims who are waiting to settle their claims against Johnson & Johnson and Bayer.

If you are a plaintiff waiting for the settlement from Johnson & Johnson and Bayer, you might be having financial difficulties due to out-of-pocket costs incurred during your medication and treatment. If this is your situation, TriMark’s Xarelto lawsuit loans may be the solution to your financial problem. 

Lawsuits were filed against multinational companies Johnson & Johnson and Bayer due to reports that they had been profiting from the sales of a dangerous drug while patients had sustained side effects. Both companies continue to claim that the drug is not defective.

The high-profile multi-district litigation cases are yet to close, and the prolonged waiting might have put the victims’ finances in jeopardy.

We understand how stressful it can be to for you to hope for a smooth recovery but couldn’t because of financial restraints. 

It may take more months or years to materialize. TriMark’s Xarelto lawsuit loans offer an alternative to plaintiffs looking for funds to cover emergency costs and daily expenses.

Request a free quote

Tell us how we can help and one of our team members will contact you shortly.

    How Xarelto Lawsuit Loans Work

    TriMark specializes in helping personal injury victims. Our pre settlement funding is a simple 3-step process:

    1. Apply for Funding

    You can apply online or by phone. We’ll answer your questions and gather some basic info about you and your case.

    2. Review & Approval

    Our underwriting team will work with your attorney to review your case and approve your request.

    3. Receive Cash

    Assuming everything looks good, we send your cash within 24 hours by wire transfer or FedEx Overnight.

    Xarelto Settlement Loans

    While negotiations are underway, you can advance a portion of your future check through a Xarelto lawsuit loan. Unlike traditional loans, this financial lifeline is a non-recourse, risk-free cash advance that plaintiffs can leverage during hard times. Apply for as high as 20% to 50% without worrying about steep interests.

    Get a Xarelto lawsuit loan quickly by tomorrow and use it on your treatment and recovery costs, daily expenses, mortgage, car loan, and other needs that may arise during the waiting period.

    This option comes with no out-of-pocket costs and monthly payments. You only pay back the advance if you win a jury award or settlement. If your case loses or does not settle, you won’t have to return the full amount.

    At TriMark, we assume all the risks. But we also approve cases based on their merits. Meaning, credit scores, income history, and employment status have no bearing on our decision.

    It is pretty safe, easy, and convenient to choose legal funding? Apply for a Xarelto lawsuit loan now and see for yourself!

    Get a Xarelto Lawsuit Loan Now

    TriMark’s Xarelto lawsuit loan application process is fast and simple. 

    You can either fill out an online form or call us at 1-(877) 932-2628 and let one of our friendly legal funding experts receive your application. The approval of your funding request will be based on the merits of your case, so make sure to submit your complete documents. 

    After you’re approved, the funds will be transferred to you in as quick as 24 hours!

    TriMark seeks to bring you financial relief, so grab this opportunity and apply now. 

    How to Qualify for Xarelto Settlement Loans

    Pre settlement and post settlement Xarelto lawsuit loans are two types of lawsuit financing provided by TriMark. They refer to funding for people with active and settled cases.

    Pending Cases:

    If you’re one of the more than 23,000 pending Xarelto cases, you qualify for pre settlement Xarelto lawsuit loans. Here are the criteria you must fulfill to ensure 100% approval:

    • A contingent-fee attorney represents you.
    • You must have sustained significant injuries from the train accident.
    • Your anticipated value should net at least $150,000 (gross award less attorney fees, case costs, medical liens, etc.).
    • Your settlement check must be deposited to, and be distributed out of, your attorney’s trust account.

    Settled Cases

    Most personal injury suits are eligible for post settlement Xarelto lawsuit loans. Make sure your net minimum value is $60,000 and relevant documentation submitted for faster processing.

    What is Xarelto?

    Xarelto is an anticoagulant, more commonly known as a blood thinner, that treats pulmonary embolism (PE) and prevents or treats deep vein thrombosis (DVT), a particular type of blood clot. It reduces the risk of blood clots in people who had knee or hip replacement surgery and risk of stroke in patients with a heart rhythm disorder called atrial fibrillation.

    The oral medication works by blocking specific proteins found in the blood. 

    Under the generic name rivaroxaban, the drug was developed by Bayer but marketed in the U.S. by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. It was patented in 2007 and approved by the Food and Drug Administration (FDA) in 2011 after an expedited regulatory review.

    Xarelto was introduced as one of the novel oral anticoagulants on the market, advertised as safe and a better, more convenient alternative to warfarin.

    This situation remains despite the thousands of lawsuits filed against the drug firms responsible for its development and distribution. Plaintiffs have alleged that these companies are profiting from the sales of a risky drug. One of the common side effects of Xarelto is bleeding, which could lead to death in some cases. 

    Traditional anticoagulants usually have an antidote in the form of vitamin K. But no affordable antidote currently exists to counteract the adverse effects of rivaroxaban, which poses another problem.

    The FDA is yet to recall Xarelto. But it has released warnings regarding its use, including the increased risk of blood clots in users who abruptly stop taking it.

    Danger, Danger: Bayer’s Blood Thinner

    The FDA issued a black box warning for Xarelto, indicating its dangers for spinal bleeding or epidural or spinal hematomas. Hematomas are pools of blood that happen outside of the blood vessels. If they occur in the spine, the patient could be permanently paralyzed.

    Blood thinners are naturally dangerous, but Bayer’s anticoagulant was the number one on the list of most dangerous published by the Institute for Safe Medication Practices (ISMP).

    The drug is also part of a list of “high-alert medications,” basically stating that when misused, the drug can increase the risk of severe harm to patients.

    Symptoms & Side Effects

    The use of Xarelto comes with various symptoms and side effects. The most alarming is bleeding, but it can range from mild to severe. Because the drug’s main job is to stop blood clot formation, continuous bleeding may occur even in the smallest cuts, which could ultimately be fatal.

    Below are more side effects of this medication. Take note that this list is incomplete, so contact your doctor immediately if other side effects occur.

    • Minor Bleeding: Bleeding from cuts and nosebleed are considered mild signs. But if they persist, let your doctor know promptly.
    • Severe Bleeding: Serious symptoms may include unusual bruising, pain and swelling, menstrual flow (heavy or prolonged), and weakness. It’s also time to call your physician if you’re bleeding more frequently in the nose, from cuts, while coughing, and while pooping.

    Extreme headaches, difficulty breathing or swallowing, and dizziness and fainting also fall under this category.

    • Allergic Reaction: This symptom is rare. But if you’re manifesting an allergic reaction, such as itching, rash, extreme dizziness, and breathing difficulty, seek medical attention immediately.
    • Other Serious Side Effects: Heavy bleeding can come with confusion, slurred speech, vision changes, and weakness, especially on one side of the body.

    According to WebMD, some people using Xarelto do not experience severe side effects. Thus, if your doctor prescribes it to you, he or she likely finds the benefits more significant than the risk of side effects.

    Lawsuits & Litigation

    More than 25,000 lawsuits were filed against Jannsen Pharmaceuticals, Johnson & Johnson, and Bayer, all of which were consolidated in multidistrict litigation (MDL) in a Louisiana federal court. The MDL is known as MDL-2592 IN RE: Xarelto (Rivaroxaban) Products Liability Litigation. U.S. District Court Judge Eldon E. Fallon oversees the trials.

    The plaintiffs accuse the three companies of negligence due to failing to research the blood clot medication adequately. The suits also say the defendant downplayed the consequences of taking the drug. Users claim they suffered from internal bleeding and hemorrhagic strokes.

    However, Xarelto’s makers won in the first three bellwether trials.

    April 2017

    Joseph Boudreaux, a 75-year-old patient from Louisiana, took Xarelto for his heart condition. He was then hospitalized for gastrointestinal bleeding. 

    The jury came up with a verdict against his case. 

    June 2017

    Joseph Orr alleged that Xarelto’s manufacturers were responsible for the death of his wife, Sharyn Orr. Also from Louisiana, Sharlyn Orr experienced a hemorrhagic stroke after taking Xarelto, falling in a coma for 10 days before passing away.

    Bayer and Jannsen won the trial.

    August 2017

    Dora Mingo developed deep vein thrombosis after hip surgery and was prescribed Xarelto. The medication resulted in gastrointestinal bleeding and acute blood loss.

    The jury favored the manufacturers, and the court denied Mingo’s motion for a new trial.

    Overall, Xarelto’s makers already faced six trials, which they all won.

    December 2017

    In a Philadelphia state court, a jury awarded nearly $27.8 million to 75-year-old Lynn Hartman from Indiana woman over the failure of Xarelto’s makers to warn users about the risks associated with their anticoagulant.

    Hartman used Xarelto to treat atrial fibrillation for a year, leading to gastrointestinal bleeding.

    However, the trial judge overturned the verdict in favor of the firms.


    DrugWatch reports that Johnson & Johnson and Bayer had 23,866 pending MDL cases as of April 2019. A month before that, the two pharmaceutical giants announced they would settle a majority of the remaining suits for $775 million.

    According to the terms of the agreement, both firms ensured the safety of the drug and claimed no liability.

    If you have a pending Xarelto case, it will be settled on the following basis:

    • There will be a significant reduction of payment for people who were prescribed Xarelto on or after December 1, 2015. The same term applies to those who first experienced a Xarelto-related injury on or before March 1, 2016. 
    • Payments will be capped for patients who got hospitalized for two consecutive days or less for an injury incurred after taking Xarelto.
    • Individuals with a Xarelto lawsuit can still join the settlement if they retained an attorney before March 11, 2019, registered their claim by March 28, 2019, and filed a lawsuit by April 4, 2019.

    How to Apply for Xarelto Settlement Funding

    Here at TriMark, we aim to provide our clients with topnotch financing products and convenient processes. Our 3-step Xarelto lawsuit loan application represents our mission and beliefs:

    1. You have two options. First, fill out an online form. The entire thing lasts only for a couple of minutes. Or second, call us to talk with one of our friendly legal funding experts, who will gladly process your application.
    2. Allow us to assess your application within 24 to 72 hours. We will base our decision on the merits of your case, so make sure to submit documents completely. 
    3. Receive your application result via call or message. If your funding request is approved, your funds will be disbursed through your chosen channel in as fast as one to 24 hours.

    Latest Developments in the Xarelto Litigation…

    The federal judge handling the $775 million settlement over the blood thinner Xarelto has established a committee of five attorneys to assess how up to $93 million set aside for leading plaintiffs firms should be doled out. U.S. District Judge Eldon Fallon of the Eastern District of Louisiana tapped Pensacola, Florida, attorney Brian Barr of Levin Papantonio Thomas Mitchell Rafferty & Proctor; Andy Birchfield of Beasley Allen in Montgomery, Alabama; Leonard Davis of Herman Herman & Katz in New Orleans; Gerald Meunier of Gainsburgh, Benjamin, David, Meunier & Warshauer, also in New Orleans; and Levin Sedran & Berman attorney Michael Weinkowitz in Philadelphia to form what the judge referred to as a “fee allocation liaison counsel” in the Xarelto litigation. The attorneys will be tasked with coming up with a recommendation for how the court should divide up the common benefit fund…. Read more
    Johnson & Johnson has been facing several lawsuits over its different products, including talc, hip-plants, and the blood thinner, Xarelto. There are a total of around 50,000 such cases against the company. The company has agreed to settle several of these cases, as announced over the last few months. However, if it were to settle all of the above 50,000 cases, it would cost the company an amount north of $6 billion, in our view. Johnson & Johnson is capable of settling all the claims if need be from its cash in hand of $14 billion. View our interactive dashboard analysis ~ How Much Money Could Johnson & Johnson Have To Shell Out To Settle Its Lawsuits? … Read more
    Johnson & Johnson has lost several major lawsuits over allegations that asbestos in its talcum powder contributes to ovarian cancer. For example, in a 2018 lawsuit, a St. Louis jury awarded almost $4.7 billion in total damages to 22 women and their families. As a strategy, the company has tried to get 2,400 of its state-court cancer lawsuits transferred to a federal court in Delaware. This would allow it to develop a single defense strategy. However, U.S. District Judge Maryellen Noreika in Wilmington, Del. dismissed the request yesterday, “noting that the world’s largest maker of health care products is partly responsible for the boomlet of litigation over its transfer strategy that it now characterizes as a crisis,” reports Bloomberg. J&J hoped that by invoking the legal rights of its talc supplier, Imerys Talc America, now bankrupt, it would create quicker trials and claims resolutions. But Noreika stated in her decision, “J&J cannot establish an emergency…. Read more
    Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed. The amount will be shared equally between the two companies that jointly developed the drug. Bayer and J&J do not admit liability under the agreement. The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs. Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information…. Read more
    Johnson & Johnson and Bayer agreed Monday to pay $775 million to settle almost 25,000 lawsuits in connection to blood thinner Xarelto. Each company will pay 50 percent of the settlement, according to The New York Times. The payment ends both state and federal cases — the New Brunswick, New Jersey-based Johnson & Johnson jointly markets Xarelto with Bayer, which is based in Germany. Patients sued both companies, which failed to issue warnings regarding possible fatal bleeding episodes connected to taking Xarelto. Neither company accepted liability and actually won all six lawsuits that went to trial. “Even in the face of meritless allegations, and even while winning in court, complex litigation demands an enormous amount of time and resources,” the pharmaceutical division of Johnson & Johnson explained in a statement regarding the settlement…. Read more
    KEY POINTS Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed. The settlement will resolve all pending U.S. lawsuits over Xarelto, which plaintiffs claimed causes uncontrollable and irreversible bleeding leading to severe injuries and even death among thousands of plaintiffs. Plaintiffs accused the drugmakers of having failed to warn about the bleeding risks, claiming their injuries could have been prevented had doctors and patients been provided adequate information. Bayer and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits over their blockbuster blood thinner Xarelto for a total of $775 million, court documents on Monday showed. The amount will be shared equally between the two companies that jointly developed the drug. Bayer and J&J do not admit liability under the agreement. The settlement will… Read more
    A Pennsylvania judge on Tuesday overturned a $27.8 million verdict against the makers of the blood thinner Xarelto in a lawsuit by an Indiana woman who claimed the drug caused severe gastrointestinal bleeding. Judge Michael Erdos issued a judgment notwithstanding the verdict because of testimony by the prescribing doctor for plaintiff Lynn Hartman. Erdos rejected an alternate ground for overturning the verdict that was based on an Instagram photo by a lawyer for the plaintiff that used the hashtag #killinnazis. Erdos nonetheless scolded and punished the lawyer for the post…. Read more
    A Pennsylvania jury awarded an Indiana woman a $28 million verdict in the state’s first Xarelto lawsuit trial. The plaintiff suffered gastrointestinal bleeding about a year after being prescribed the blood-thinning drug, according to a press release. The verdict followed nearly a month of testimony in court of Common Pleas. The plaintiff’s attorneys accused Johnson & Johnson and Bayer of downplaying the potentially life-threatening side effects of the Xarelto drug. It took the jury less than two days to come to a verdict, awarding the plaintiff and her husband $1.8 million in compensatory damages and $26 million in punitive damages. Pharmaceutical giants Bayer and Johnson & Johnson have been named in more than 20,000 lawsuits related to the Xarelto drug. Approximately 2,000 of those lawsuits are part of the mass tort program in Philadelphia…. Read more
    A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers’ blood thinner Xarelto led to severe internal bleeding. The verdict in U.S. District Court in Jackson, Mississippi, is a blow to thousands of patients with similar allegations against the drugmaker. The jury returned the verdict after just four hours of deliberation. The companies also won the previous two trials on claims of risks from Xarelto. In the latest case, plaintiff Dora Mingo claimed she suffered acute gastrointestinal bleeding after she was treated with Xarelto for a month in 2015 to prevent blood clotting following an operation. She accused the drugmakers, who jointly developed the blood thinner, of having failed to warn about the bleeding risks and said her injuries could have been prevented had they provided adequate information…. Read more
    As the number of lawsuits against the blood thinner Xarelto continues to climb, so do reports of injuries and deaths caused by the controversial anticoagulant, according to a recent study by the Institute for Safe Medication Practices (ISMP). According to ISMP, the U.S. Food and Drug Administration received 15,043 reports of serious injury or death linked to Xarelto last year — a 41 percent increase over the previous year. ISMP, a non-profit organization that monitors and analyzes adverse drug events reported to the government, published the findings in its annual edition of QuarterWatch.  Oral blood thinners such as Xarelto caused more emergency room visits in 2016 than any other class of drugs, ISMP found. The group said it identified nearly 22,000 reports of severe injury, including 3,018 deaths. Nearly all of the injuries were from internal bleeding, the report states. Of the five anticoagulants implicated, rivaroxaban, sold under the brand name… Read more
    A month after drugmakers Johnson & Johnson and Bayer prevailed in the first trial over allegations of harm caused by the blood thinner Xarelto, the second bellwether case has gone to trial in New Orleans. This time, the family of a woman who died about a year after she started taking the drug for atrial fibrillation is accusing the drugmakers of responsibility for her fatal hemorrhagic stroke. Sharyn Orr, of Louisiana, died in May 2015 at the age of 67 after being in a coma for 10 days. The family’s lawyers say her death was “completely avoidable.”… Read more
    The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week, with 18,000 more cases stacked up behind it. It will be the initial indicator of whether juries are likely to side with the drugmakers, ruling that their med is safe and effective, or patients, who claim the two companies hid the real risks of the blood thinner. The case in New Orleans was brought by Joseph Boudreaux, who took the drug to cut his stroke risk but claims it caused internal bleeding that caused heart problems and resulted in a visit to intensive care unit for a week, the Chicago Tribune reported. In their defense, J&J and Bayer point out that the FDA has deemed the drug safe and effective and that the risks it holds are clearly laid out on its label…. Read more
    Joseph Boudreaux says taking Johnson & Johnson's blood-thinning drug Xarelto was one of the biggest mistakes of his life. While Xarelto was supposed to help cut his stroke risk, Boudreaux says it instead caused internal bleeding that required a week-long hospital stay in the intensive-care unit, several blood transfusions and multiple heart procedures. "I don't want anybody else to suffer like I have from that drug," the part-time security guard says. Starting Monday, Boudreaux will get a chance to have jurors hold J&J and Bayer, which jointly developed Xarelto, responsible for the treatment's potentially fatal side effects as his case in New Orleans becomes the first lawsuit targeting the medicine to go to trial. The companies are facing more than 18,000 U.S. patient suits blaming the blood thinner for internal bleeding. The medicine also has been linked to at least 370 deaths, according to Food and Drug Administration reports…. Read more
    After critics accused Johnson & Johnson and Bayer of hiding data in clinical trials for their blockbuster blood thinner Xarelto (rivaroxaban), the U.S. Food and Drug Administration said the drug is safe and effective. Since its approval in 2011, Xarelto has made billions for J&J and Bayer. On Oct. 11, 2016, the FDA released its reanalysis of the ROCKET AF clinical trial data — the original trial used to approve Xarelto. According to the agency, the drug is still a safe and effective alternative to warfarin despite a faulty device used in the clinical trials. The FDA conducted the reanalysis after The BMJ and other critics questioned trial results following the discovery that the INRatio — a device used to administer warfarin to patients in the trial — was faulty. In 2014, the FDA recalled the INRatio device because it could deliver significantly lower results than a lab method, resulting in warfarin patients… Read more
    Lawyers for patients suing Johnson & Johnson and Bayer over severe bleeding injuries caused by the blockbuster blood thinner Xarelto say the drug makers failed to provide clinical trial data, the New York Times reported. Documents filed in court say a re-analysis conducted by Duke published by the New England Medical Journal of Medicine was missing key information that could have affected clinical trial data comparing Xarelto to warfarin in its 2011 ROCKET-AF study. J&J and Bayer stayed silent and helped deceive editors of the journal, lawyers said. The trial in question compared the safety of Xarelto and warfarin. Specifically, it collected data on the number of strokes and bleeding events experienced by patients taking one drug or the other. According to the study results, both Xarelto and warfarin had the same risk of bleeding, but J&J and Bayer’s drug showed fewer incidents of bleeding in the brain and fatal… Read more
    Hundreds of people filed lawsuits against Bayer and Johnson & Johnson claiming their blood-thinning drug Xarelto (rivaroxaban) caused them to suffer negative side effects like uncontrollable bleeding. Now, the daughter of a Florida man who died from a stroke four days after he began taking Xarelto filed a lawsuit in Philadelphia claiming the drug did not work as advertised. It’s the first lawsuit claiming Xarelto failed to prevent a stroke in a patient with atrial fibrillation (abnormal heartbeat). The U.S. Food and Drug Administration approved Xarelto to reduce the risk of stroke in patients with atrial fibrillation in 2011, but one FDA reviewer recommended against the drug’s approval…. Read more
    Big Pharma started 2015 with the news that two U.S. courts consolidated groups of Xarelto lawsuits that claim the blood thinner caused severe bleeding, some of which caused drug recipients to die. An oral blood thinner developed and sold by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Xarelto (rivaroxaban), hit the U.S. market in July 2011 and quickly grew into a popular alternative to an older medication, warfarin. The drug’s makers marketed the drug as superior to warfarin. Unlike warfarin, Xarelto has no dietary restrictions or blood tests but causes more gastrointestinal bleeds. This excessive bleeding led to serious complications, and patients and families soon turned to litigation as compensation for damages. The first consolidation order came in December 2014 when the U.S. Judicial Panel on Multidistrict District Litigation (JPML) transferred about two dozen cases in Louisiana federal court. The defendants, drug giants Bayer and Johnson & Johnson’s Janssen Pharmaceuticals… Read more

    See More